| 書(shū)目名稱 | Resistance of Targeted Therapies Excluding Antibodies for Lymphomas |
| 編輯 | Andrés J. M. Ferreri |
| 視頻video | http://file.papertrans.cn/829/828447/828447.mp4 |
| 概述 | This book will focus on recently developed targeted therapies other than monoclonal antibodies used in lymphoma patients, both in routine practice and investigative trials.Divided by groups of drugs, |
| 叢書(shū)名稱 | Resistance to Targeted Anti-Cancer Therapeutics |
| 圖書(shū)封面 |  |
| 描述 | .In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.. |
| 出版日期 | Book 2018 |
| 關(guān)鍵詞 | Lymphomas; Malignancies; Investigative trials; Resistance; Relapse |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-319-75184-9 |
| isbn_softcover | 978-3-030-09165-1 |
| isbn_ebook | 978-3-319-75184-9Series ISSN 2196-5501 Series E-ISSN 2196-551X |
| issn_series | 2196-5501 |
| copyright | Springer International Publishing AG, part of Springer Nature 2018 |
|Archiver|手機(jī)版|小黑屋|
派博傳思國(guó)際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-8 09:32
發(fā)表于 2025-3-21 17:34:41
